London: A third ‘booster’ dose of Covid-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings. Published as a research letter in The Lancet, researchers including from the Francis Crick Institute and UCLH Biomedical Research, found that antibodies generated in people who had received only two doses of either the […]
Pregnant individuals reported pain at the injection site more frequently than their nonpregnant counterparts but fewer follow-up symptoms such as headache, chills, muscle pain and fever.
According to CNN, blood serum samples from people who had received two doses of the Pfizer-BioNtech vaccine "efficiently" neutralised a version of the virus.
The research, published in the journal Nature Medicine, noted that the vaccine is effective against coronavirus variants carrying the N501Y and E484K mutations.
"While these findings do not indicate the need for a new vaccine to address the emerging variants, the companies are prepared to respond if a variant of SARS-CoV-2 demonstrates evidence of escaping immunity by the Covid-19 vaccine," Pfizer and BioNTech said in a statement on Wednesday.
In a yet-to-be peer reviewed research, scientists from the University of Texas Medical Branch, tested the ability of blood serum from 20 individuals immunised with the Pfizer-BioNTech vaccine to neutralise coronavirus engineered to carry the new mutations
